Peptide Injection Sites: Subcutaneous vs Intramuscular Guide

Most research peptides and FDA-approved GLP-1 receptor agonists are administered by subcutaneous injection — into the fatty tissue just beneath the skin. This is the default route for semaglutide, tirzepatide, liraglutide, ipamorelin, CJC-1295, BPC-157, TB-500, sermorelin, tesamorelin, and most other peptides used in clinical and research settings.

Subcutaneous delivery produces a slower, more sustained absorption pattern that matches the pharmacokinetics of most peptides. The fatty tissue acts as a depot, releasing the peptide gradually into circulation. The injection itself uses a short, fine needle (typically 29-31 gauge, 5/16" to 1/2" long) and is essentially painless when performed correctly.

Intramuscular injection — delivering the peptide into muscle tissue — is used less frequently for peptides. Some protocols for BPC-157 administered at a specific injury site use IM delivery to concentrate the peptide locally. A few peptides used in hormone-replacement contexts may be given IM depending on formulation. Intramuscular injection uses a longer needle (typically 22-25 gauge, 1" to 1.5") and carries slightly higher risk of hitting blood vessels or nerves if performed incorrectly.

The default assumption for any peptide discussed on PeptideMark is subcutaneous unless the prescribing clinician or study protocol specifies otherwise.

Three body regions are considered safe and practical for subcutaneous peptide injection:

Abdomen. The area at least two inches from the navel and avoiding the belt line. This is the most commonly used site for GLP-1 agonists and most research peptides. The abdomen has the most consistent subcutaneous fat thickness, the absorption rate is predictable, and self-injection is easy.

Outer thigh. The front-outer region of the upper thigh, about halfway between the hip and knee. Easily accessible for self-injection. Absorption can be slightly faster than abdomen, which may matter for compounds where onset timing is relevant.

Back of upper arm. The fatty tissue on the back of the upper arm, between the shoulder and elbow. Requires a partner to inject if you want to reach this site cleanly. Less commonly used.

Areas to avoid entirely. Stretch marks, scar tissue, bruised or broken skin, visible veins, the two-inch radius around the navel, and any area that has been injected within the past 7-14 days.

Fat thickness matters. If a subcutaneous injection accidentally reaches muscle tissue, absorption can be faster and more variable, which can change dosing response. Very lean individuals may need to pinch the skin to create a clear subcutaneous depot, or angle the needle at 45 degrees rather than 90 degrees.

Rotating injection sites is essential for three reasons: preventing lipohypertrophy (fatty lumps that form from repeated injection in the same spot), preserving absorption consistency, and reducing localized irritation.

Lipohypertrophy risk. Repeated injection into the same skin region can produce subcutaneous fatty nodules over weeks to months. These nodules impair absorption — the peptide either releases too slowly or erratically, which can reduce efficacy. This is a well-documented complication in insulin therapy and applies to any peptide administered by recurring subcutaneous injection.

A simple rotation scheme. Divide each injection region (for example, the abdomen) into a grid of at least 4-6 zones. Use each zone once before returning to it, and leave at least 2 weeks between injections in any single zone. If you inject daily, rotate through all available zones across abdomen, thighs, and arms.

Common mistake. Repeatedly injecting at "the spot that works" — usually a zone with less pain sensation — is exactly how lipohypertrophy develops. Pain sensation decreases over time because local nerves adapt, not because that zone is safer. Rotate regardless of comfort.

Tracking. A simple injection log (date, site, dose) on paper or phone notes prevents accidental clustering. Some patients mark a rotation pattern on a printed body diagram and cross off each zone as used.

General subcutaneous technique, applicable to most peptide administration:

1. Wash hands thoroughly with soap and water. 2. Check the vial label, dose, and expiration date. Confirm the solution is clear (or the expected color for that compound) and free of visible particulates. 3. Wipe the vial stopper and the injection site with an alcohol swab. Let both air-dry for 15-30 seconds — injecting while alcohol is still wet causes stinging. 4. Draw the prescribed dose into an appropriately sized insulin syringe (typically 0.3 mL or 0.5 mL barrel, 29-31 gauge, 5/16" needle). 5. Tap out visible air bubbles and push the plunger slightly until a small droplet appears at the needle tip. 6. Pinch a fold of skin in the chosen zone. Insert the needle at 90 degrees (or 45 degrees if you are very lean). 7. Release the pinch and inject steadily over 2-3 seconds. 8. Withdraw the needle at the same angle you entered. Do not rub the site. 9. Apply gentle pressure with a clean gauze or cotton ball if there is any bleeding. 10. Dispose of the used syringe in a sharps container immediately. Never recap needles.

Aspiration. For subcutaneous injection, aspiration (pulling back on the plunger to check for blood return) is generally not required. Major guidelines for insulin and GLP-1 injections do not recommend aspiration for subcutaneous delivery.